Marie Wikström Lindholm
Directeur Technique/Scientifique/R&D chez SILENCE THERAPEUTICS PLC
Postes actifs de Marie Wikström Lindholm
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SILENCE THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 01/12/2023 | - |
| Corporate Officer/Principal | 02/11/2020 | 01/12/2023 | |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Directeur/Membre du Conseil | 18/01/2022 | - |
Historique de carrière de Marie Wikström Lindholm
Anciens postes connus de Marie Wikström Lindholm
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| University of Lund | Corporate Officer/Principal | 01/01/1999 | 01/01/2000 |
Formation de Marie Wikström Lindholm
| University of Uppsala | Doctorate Degree |
Statistiques
Internationale
| Suède | 3 |
| Royaume-Uni | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Commercial Services | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Bourse
- Insiders
- Marie Wikström Lindholm
- Expérience